…merging metric in MS research is the proportion of patients who are disease-activity free (DAF), defined as no relapses, no MRI activity (T2 or Gd+ T1 lesions) and no sustained EDSS progression. One of the first uses was an analysis of the AFFIRM dataset, which reported a two-year DAF rate of 37% with natalizumab versus 7% with placebo (Havrdova et al. Lancet Neurol 2009;8:254-260). Subscribe to read more It takes 30 seconds or login using your em…

…ADEMY OF NEUROLOGY (AAN) ANNUAL MEETING, SAN DIEGO, CA, MARCH 16-23, 2013 – An integrated analysis of BG-12 trials indicates that there is a low incidence of serious adverse events during treatment although flushing and gastrointestinal effects are common (Phillips et al. AAN 2013; abstract S30.003). Subscribe to read more It takes 30 seconds or login using your email address Please enter the email address that you registered the newsletter with C…

…REPORT FROM THE AMERICAN ACADEMY OF NEUROLOGY (AAN) ANNUAL MEETING, SAN DIEGO, CA, MARCH 16-23, 2013 – A second-generation STRATIFY assay produces a lower false-negative rate and less variability in serostatus results compared to the original STRATIFY-1 test, according to the latest data. Subscribe to read more It takes 30 seconds or login using your email address Please enter the email address that you registered the newsletter with Continue…

…n volume was measured using SIENA/SIENAX. Data were analysed for the two-year placebo-controlled FREEDOMS and FREEDOMS II trials, and the one-year TRANSFORMS trial comparing fingolimod to interferon-beta-1a IM. Subscribe to read more It takes 30 seconds or login using your email address Please enter the email address that you registered the newsletter with Continue…